Effects of Whole-body Electromyostimulation and Dietary Supplements on "Sarcopenic Obesity"
NCT ID: NCT02356016
Last Updated: 2016-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
75 participants
INTERVENTIONAL
2013-08-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Whole-body Electromyostimulation Versus Conventional Low-volume Strength Training in Overweight Individuals
NCT03306056
Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue
NCT01793896
Muscle Lipid and Insulin Resistance in the Elderly
NCT00765505
Efficacy of Whole-body Electromyostimulation (WB-EMS) Training in Participants With Pre-diabetes
NCT06188481
Home-based Training in Obese Individuals
NCT05773690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Whole body Electromyostimulation (WB-EMS)
18 min of WB-EMS/week (one session/week)
WB-EMS Intervention
Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
WB-EMS and Nutritional Supplements
18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
WB-EMS-Intervention and dietary supplementation
Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
Control
Monthly dietary counseling for 6 months
control (dietary counseling)
Monthly dietary counseling only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WB-EMS Intervention
Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
WB-EMS-Intervention and dietary supplementation
Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
control (dietary counseling)
Monthly dietary counseling only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sarcopenic Obesity
Exclusion Criteria
* more than 4 weeks absent during the interventional period,
* injuries (i.e. hip TotalEndoProsthesis (TEP), abdomen/groin hernia) or diseases (i.e. epilepsy, cardiac arrhythmia) that prevent WB-EMS intervention
* medication and/or diseases affecting our primary endpoints.
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg
OTHER
Bavarian Research Foundation, Munich, Germany
UNKNOWN
miha bodytec, Gersthofen, Germany
UNKNOWN
Physiomed, Laipersdorf, Germany
UNKNOWN
Siemens AG
INDUSTRY
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cornel Sieber, MD
Role: STUDY_CHAIR
Institute of Biomedicine of Age, University of Erlangen-Nuremberg
Cornelius Bollheimer, MD
Role: STUDY_CHAIR
Institute of Biomedicine of Age, University of Erlangen-Nuremberg
Klaus Engelke, PhD
Role: STUDY_DIRECTOR
Institute of Medical Physics, University of Erlangen-Nuremberg
Wolfgang Kemmler, PHD
Role: PRINCIPAL_INVESTIGATOR
Institute of Medical Physics, University of Erlangen-Nuremberg
Ellen Freiberger, PhD
Role: PRINCIPAL_INVESTIGATOR
Institute of Biomedicine of Age, University of Erlangen-Nuremberg
References
Explore related publications, articles, or registry entries linked to this study.
Kemmler W, Bebenek M, Engelke K, von Stengel S. Impact of whole-body electromyostimulation on body composition in elderly women at risk for sarcopenia: the Training and ElectroStimulation Trial (TEST-III). Age (Dordr). 2014 Feb;36(1):395-406. doi: 10.1007/s11357-013-9575-2. Epub 2013 Aug 16.
Kemmler W, von Stengel S. Whole-body electromyostimulation as a means to impact muscle mass and abdominal body fat in lean, sedentary, older female adults: subanalysis of the TEST-III trial. Clin Interv Aging. 2013;8:1353-64. doi: 10.2147/CIA.S52337. Epub 2013 Oct 7.
Kemmler W, Teschler M, Weissenfels A, Bebenek M, von Stengel S, Kohl M, Freiberger E, Goisser S, Jakob F, Sieber C, Engelke K. Whole-body electromyostimulation to fight sarcopenic obesity in community-dwelling older women at risk. Resultsof the randomized controlled FORMOsA-sarcopenic obesity study. Osteoporos Int. 2016 Nov;27(11):3261-3270. doi: 10.1007/s00198-016-3662-z. Epub 2016 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FORMOsA P2 TP3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.